HONGENE BIOTECH

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 10 May 2024 filing date already counts against anyone who files later.

Record

Serial number

98544404

Mark type

Design + words

Filed

10 May 2024

Published for opposition

11 Mar 2025

Attorney of record

Michael T. Smith

Goods and services

• Class 001 — Chemicals: adjuvants, other than for medical or veterinary purposes; bases in the nature of alkalies being chemical preparations; biochemical catalysts; biological preparations for use in industry and science, other than for medical or veterinary purposes; carbonic hydrates; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations for research laboratory use; diagnostic preparations, other than for medical or veterinary purposes; enzyme preparations for industrial purposes; enzymes for industrial purposes; ferments for chemical purposes, namely, fermentation extract; glucose for industrial purposes, namely, glucosides; industrial chemicals; isotopes for industrial purposes preparations of microorganisms, other than for medical and veterinary use; salts being chemical preparations; sulfides
• Class 005 — Pharmaceuticals: biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; capsules sold empty for medicines; chemical preparations for medical purposes for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for pharmaceutical purposes; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; diagnostic preparations for veterinary purposes; drugs being pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; ferments for pharmaceutical purposes; immunostimulants; isotopes for medical purposes; medical preparations for slimming purposes; medicinal hair growth preparations; medicines for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss for human purposes; medicines for veterinary purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceutical preparations for treatment and prevention cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceuticals for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; phosphates for pharmaceutical purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; preparations of microorganisms for medical or veterinary use; vaccines; veterinary preparations for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss

Owner

• SHANGHAI HONGENE BIOTECH CORPORATION, Shanghai, CN
• SHANGHAI HONGENE BIOTECH CORPORATION, Shanghai, CN

Prosecution history

• 06 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
• 13 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
• 13 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
• 13 May 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
• 06 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 11 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 11 Mar 2025 — PUBLISHED FOR OPPOSITION
• 05 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 14 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 13 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 13 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 13 Feb 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 25 Nov 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 25 Nov 2024 — NON-FINAL ACTION E-MAILED
• 25 Nov 2024 — NON-FINAL ACTION WRITTEN